Predictive Accuracy of HeartMate 3 Risk Score After the Heart Transplant Allocation Change
The HeartMate 3 risk score (HM3RS) was developed from the Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate 3 (MOMENTUM 3) clinical trial to predict 1 and 2 year mortality after left ventricular assist device implantation. However, it has not been validated in a real-world population, especially after the heart transplant allocation system change on October 18, 2018. In this multicenter retrospective analysis, we found that HM3RS did not predict 1 and 2 year outcomes in the contemporary era, highlighting the need to revise this risk prediction tool in the real-world setting.
Authors
- Elena Deych (ORCID: https://orcid.org/0000-0002-6083-3579)
- Erin Coglianese (ORCID: https://orcid.org/0000-0002-8144-9031)
- Justin Vader (ORCID: https://orcid.org/0000-0002-8198-3437)
- David S. Lambert
- Bin Yang (ORCID: https://orcid.org/0000-0002-9653-145X)
- Ana María Picó
- Justin D. Vincent
- Alyssa Ramsay
Institutions
- Harvard University (US)
- Washington University in St. Louis (US)
- Massachusetts General Hospital (US)
Publication Details
- Journal
- ASAIO Journal
- Published
- 2024-11-05
- DOI
- https://doi.org/10.1097/mat.0000000000002343
- Citations
- 1
- Primary Topic
- Mechanical Circulatory Support Devices
- Type
- article
- Field-Weighted Citation Impact
- 0.18